Ionis Pharmaceuticals Inc
IONS43.000USD
-0.590-1.35%
Close 07/03, 13:00（ET）Quotes delayed by 15 min
6.84BMarket Cap
LossP/E TTM
More Details of Ionis Pharmaceuticals Inc Company
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Company Info
Ticker SymbolIONS
Company nameIonis Pharmaceuticals Inc
IPO dateMay 17, 1991
Founded at1991
CEODr. Brett P. Monia, Ph.D.
Number of employees1069
Security typeOrdinary Share
Fiscal year-endMay 17
Address2855 Gazelle Court
CityCARLSBAD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92010
Phone17609319200
Websitehttps://www.ionis.com/
Ticker SymbolIONS
IPO dateMay 17, 1991
Founded at1991
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
32.25K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Shareholding Stats
Updated: Thu, Jul 3
Updated: Thu, Jul 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
Shareholder Types
Shareholders
Proportion
Investment Advisor
67.26%
Investment Advisor/Hedge Fund
28.07%
Hedge Fund
13.12%
Research Firm
2.36%
Private Equity
1.60%
Sovereign Wealth Fund
1.08%
Pension Fund
0.93%
Individual Investor
0.81%
Bank and Trust
0.52%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
787
184.68M
116.03%
+8.73M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
Capital Research Global Investors
10.50M
6.6%
+10.50M
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Name
Proportion
ARK Genomic Revolution ETF
3.36%
Tema Neuroscience and Mental Health ETF
2.73%
Capital Group US Small and Mid Cap ETF
2.15%
Virtus LifeSci Biotech Products ETF
1.66%
SPDR S&P Biotech ETF
1.45%
Tema Cardiovascular and Metabolic ETF
1.25%
WisdomTree BioRevolution Fund
1.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Franklin Genomic Advancements ETF
0.62%
Invesco NASDAQ Future Gen 200 ETF
0.61%
View more
ARK Genomic Revolution ETF
Proportion3.36%
Tema Neuroscience and Mental Health ETF
Proportion2.73%
Capital Group US Small and Mid Cap ETF
Proportion2.15%
Virtus LifeSci Biotech Products ETF
Proportion1.66%
SPDR S&P Biotech ETF
Proportion1.45%
Tema Cardiovascular and Metabolic ETF
Proportion1.25%
WisdomTree BioRevolution Fund
Proportion1.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.86%
Franklin Genomic Advancements ETF
Proportion0.62%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.61%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
